Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80639 |
Name | bone sarcoma |
Definition | A bone cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02389244 | Phase II | Regorafenib | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) | Recruiting | FRA | 0 |
NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Active, not recruiting | FRA | 0 |
NCT03838042 | Phase Ib/II | Entinostat + Nivolumab | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) | Recruiting | SWE | NLD | FRA | DEU | CHE | AUT | AUS | 0 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT04055220 | FDA approved | Regorafenib | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA) | Recruiting | FRA | 0 |
NCT04698785 | Phase II | Regorafenib | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN) | Recruiting | FRA | 0 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT05253131 | Phase Ib/II | AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib | Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas | Not yet recruiting | USA | 0 |
NCT05621668 | Phase I | AttIL12 T-cells + Cyclophosphamide | A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma | Recruiting | USA | 0 |
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |